Key result
Dietary supplementation with homoarginine improved cardiac function in a murine model of chronic heart failure post-myocardial infarction.
Why the study?
Does dietary supplementation with homoarginine improve cardiac function in a murine model of post-myocardial infarction heart failure?
Does dietary supplementation with homoarginine improve cardiac function in a murine model of post-myocardial infarction heart failure?
Dietary supplementation with homoarginine preserves cardiac function in a murine model of post-MI heart failure, suggesting a potential novel preventive strategy.
No immediate clinical implications from murine data; leaves open translation of homoarginine benefits to human post-MI heart failure.
Low plasma homoarginine (HA) is an emerging biomarker for cardiovascular disease and an independent predictor of mortality in patients with heart failure. Plasma levels appear to reflect cardiac dysfunction, positively correlating with ejection fraction and inversely with circulating brain natriuretic peptide. However, whether this outcome is a bystander or cause-and-effect has yet to be established. Within the context of stroke, a direct causal relationship has been inferred because normal mice pretreated with 14 mg/L HA had a smaller stroke size. In the present study, we show for the first time that dietary supplementation with HA improves cardiac function in the setting of chronic heart failure, suggesting a novel preventive strategy and inferring that low HA levels may be inherently detrimental because of a loss of this effect.
No takes yet. Share an insight, caveat, or question.
Atzler et al. (2017) studied Post-Myocardial Infarction Heart Failure. Dietary supplementation with homoarginine was evaluated on Cardiac function. Dietary supplementation with homoarginine improved cardiac function in a murine model of chronic heart failure post-myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: